Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
Clin Transl Oncol
; 19(10): 1193-1198, 2017 Oct.
Article
em En
| MEDLINE
| ID: mdl-28612203
Nowadays and given the improvement in response rate with the new schemes of treatment with chemotherapy, the interest in neoadjuvant treatment for pancreatic ductal adenocarcinoma, allowing the early application of systemic therapies, has also increased. However, treatment selection fundamentally depends on decisions taken by multidisciplinary committees due to the absence of randomized trials on this indication and because the available evidence is based primarily on small studies. The present manuscript tries to establish recommendations based on the available evidence and expert opinion to correctly select the indication, the type of treatment, as well as its duration and how to correctly follow-up patients during treatment with chemotherapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Adenocarcinoma
/
Terapia Neoadjuvante
/
Carcinoma Ductal Pancreático
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Humans
Idioma:
En
Revista:
Clin Transl Oncol
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Espanha
País de publicação:
Itália